AstraZeneca on Monday reported that the combination of Lynparza (olaparib) and Imfinzi (durvalumab) more than doubled the median duration of response in patients with mismatch repair proficient endometrial cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,